Atherosclerosis Treatment Drugs Market with Major Provincial Sectors, key players such as GlaxoSmithKline plc. Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Isis Pharmaceuticals, Inc.
Atherosclerosis is characterized by the narrowing and hardening of the arteries. In this condition, arteries become blocked by fatty substances, such as cholesterol. These substances are called as plaques or atheroma. The risks of atherosclerosis increase with age. The deposition of plaque tends to narrow the arterial canal, which result in the limited flow of blood and oxygen through it. Atherosclerosis commences with damage to the endothelium of arteries leading to the formation of plaque. This condition is dangerous for the vital organs such as heart and brain. The risk associated with atherosclerosis includes serious cardiovascular and brain diseases. Collectively, these conditions are more common for cardiovascular diseases (CVD) including coronary heart disease, angina pectoris, and transitory ischemia. Other risks for atherosclerosis are carotid artery disease, kidney disease, and peripheral artery disease.
Download PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2430
Atherosclerosis Treatment Drugs Market – Driver
Increasing number of pipeline studies and rising involvement of key players for developing the treatment options for atherosclerosis are expected to propel atherosclerosis treatment drugs market growth. For Instance, in November 13, 2018, Bayer in collaboration with Janssen, LP started the clinical study for Rivaroxaban and Acetylsalicylic Acid to build up the insights in treatment patterns and to study results of Rivaroxaban (Xarelto) in combination with acetylsalicylic acid (xatoa) prescribed to patients with atherosclerosis. The study is estimated to complete in August 2021.